EODData

MEMBERSHIP REGISTER LOG IN

FRA, 6Z4: Crinetics Pharmaceuticals Inc

25 Sep 2025
LAST:

29.80

CHANGE:
 0.00		OPEN:
29.80		HIGH:
29.80		ASK:
0.00		VOLUME:
500
CHG(%):
0.00		PREV:
29.80		LOW:
29.80		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
25 Sep 2529.8029.8029.8029.80500
24 Sep 2529.8029.8029.8029.80500
23 Sep 2528.0030.0028.0030.00500
22 Sep 2528.8028.8028.8028.8010
19 Sep 2530.0030.0030.0030.0010
18 Sep 2529.0029.0029.0029.0010
15 Sep 2529.0029.0029.0029.0010
12 Sep 2528.6028.6028.6028.6010
11 Sep 2529.2029.2029.2029.2010
10 Sep 2530.8032.0030.8032.0010

COMPANY PROFILE

Name:Crinetics Pharmaceuticals Inc
About:Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; SST3 Agonist program for the treatment for autosomal dominant polycystic kidney disease; and Radionetics for multiple solid-tumors, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Sector:Healthcare
Industry:Biotechnology
Address:6055 Lusk Boulevard, San Diego, CA, United States, 92121
Website:https://www.crinetics.com
ISIN:US22663K1079
LEI:549300Q1CNFXK5P31D28

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:29.68
MA10:29.62
MA20:28.75
MA50:26.77
MA100:26.75
MA200:31.36
STO9:85.71
STO14:35.29
RSI14:55.56
WPR14:-64.71
MTM14:0.20
ROC14:0.01
ATR:0.96
Week High:30.00
Week Low:28.00
Month High:32.00
Month Low:25.80
Year High:56.76
Year Low:22.35